Phaarmasia

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE486I01016
NSEID:
BSEID: 523620
View on BSE

INR

82.60

-3.2 (-3.73%)

BSENSE

Sep 04, 03:30 PM

BSE+NSE Vol: 2.62 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Kabra Drugs

Samrat Pharma

Ajooni Biotech

Vasundhara Rasy.

Source Natural

Phaarmasia

Biofil Chemicals

Mangalam Drugs

Bharat Immunolog

Shelter Pharma

Zenith Drugs

Why is Phaarmasia Ltd ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.45%

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.15

Flat results in Jun 26

NET SALES(Q) At Rs 8.28 cr has Fallen at -29.8% (vs previous 4Q average)
PAT(Q) At Rs 0.34 cr has Fallen at -33.7% (vs previous 4Q average)

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Phaarmasia for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Phaarmasia

142.94%

2.14

66.82%

Sensex

-5.21%

-0.39

13.39%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

21.27%

EBIT Growth (5y)

25.15%

EBIT to Interest (avg)

-1.15

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

2.35

Tax Ratio

17.49%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.06%

ROCE (avg)

-10.15%

ROE (avg)

1.45%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.40

EV to EBIT

35.10

EV to EBITDA

31.63

EV to Capital Employed

5.58

EV to Sales

1.18

PEG Ratio

0.12

Dividend Yield

ROCE (Latest)

ROE (Latest)

19.76%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET SALES(Latest six months)

At Rs 16.01 cr has Grown at 30.16%

-6What is not working for the Company

NET SALES(Q)

At Rs 8.28 cr has Fallen at -29.8% (vs previous 4Q average

PAT(Q)

At Rs 0.34 cr has Fallen at -33.7% (vs previous 4Q average

Loading Valuation Snapshot...

Here's what is not working for Phaarmasia

Net Sales - Quarterly

At Rs 8.28 cr has Fallen at -29.8% (vs previous 4Q average)

over average Net Sales of the previous four quarters of Rs 11.80 Cr

MOJO Watch

Near term sales trend is very negative

Net Sales (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 0.34 cr has Fallen at -33.7% (vs previous 4Q average)

over average PAT of the previous four quarters of Rs 0.51 Cr

MOJO Watch

Near term PAT trend is very negative

PAT (Rs Cr)